Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

blogs

Sanofi reception

Sanofi moves closer to arthritis drug filing

Reports positive late-stage results for sarilumab

Sanofi reception

Sanofi pulls development of blood cancer drug

Fedratinib linked to brain disorder during clinical trials

- PMLiVE

How Pfizer reclaimed its Twitter brand

Company explains how it took back its name on the social network

Pfizer finally acquires the @pfizer name on Twitter

Will streamline its existing @pfizer_news account

Sanofi reception

Sanofi returns to growth in Q3

Diabetes products and Genzyme help company overcome patent cliff

- PMLiVE

Sanofi launches a monster mobile diabetes game

Monster Manor iPhone and Android apps aim to encourage better management of the condition

Sanofi reception

Sanofi and Regeneron’s cholesterol antibody aces phase III trial

Results confirm companies' lead over Amgen, Pfzer, Roche and Novartis

- PMLiVE

Novartis adds Facebook personalisation to sight campaign

Features the viewer's own pictures from the social network

Sanofi reception

Nasacort approval cements Sanofi’s OTC ambitions

Can sell allergy spray directly to consumers in US

The social world of serendipity

Going beyond ‘fishing where the fish are’

Sanofi reception

EASD 2013: Sanofi prepared for biosimilar threat to Lantus

Next generation insulin U300 set to launch at time of patent expiration

- PMLiVE

EASD 2013: Sanofi justifies decision to withdraw US filing for Lyxumia

Takes issue with FDA's narrow risk-benefit focus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links